25
Nov
2019
Tag: CAR-T
28
Oct
2019
Bionest
Long Awaited CMS Rules on Medicare Coverage for CAR-T Therapies
In August, the Centers for Medicare and Medicaid Services (CMS) finalized long-sought rules framing the coverage of chimeric antigen receptor T-cell (CAR-T) treatments. Two CAR-T therapeutics are currently on the market: Gilead’s Yescarta and Novartis’ Kymriah, both approved for diffuse large B-cell lymphoma (DLBCL) with the latter also approved for acute lymphocytic leukemia (ALL). Under...
4
Mar
2019
Bionest
Targeting Brain Cancer with New Vaccine Approaches
Glioblastoma multiforme (GBM) is the most common form of brain cancer affecting adults. It is also one of the deadliest and hardest to treat cancers. About half of all people with GBM survive longer than 18 months, but only 15% are still alive five years post diagnosis. Of the approximately two dozen experimental treatments tested...
7
Jan
2019
Bionest
Multiple Myeloma: The View from ASH 2018
Multiple myeloma (MM) is a deadly bone marrow cancer. In recent years, the treatment landscape for this disease has improved considerably. However, most patients still relapse and the need for new and better therapeutic options endures. Encouraging news about several approaches were reported at the American Society of Hematology (ASH) in December. Results from...
23
Jul
2018
Bionest
Analysts’ Predictions on Top 10 Best Selling Drugs in 2024 — And Our Take
Market analyst firm Evaluate released their annual report, “EvaluatePharma World Preview 2018: Outlook to 2024,” last month. The report predicts that worldwide prescription drug sales will grow to over $1.2 trillion over the next six years. Novartis is projected to be 2024’s leading prescription drug company with $53.2 billion in overall sales, followed by Pfizer...
2
Jul
2018
Bionest
A Few Takeaways from ASCO 2018 — Part One
Precision medicine was an important theme of ASCO 2018 — the annual meeting of the American Society of Clinical Oncology — with this year’s meeting subtitled as “Delivering Discoveries, Expanding the Reach of Precision Medicine.” This theme was reflected not only in discussions around molecular profiling of patients, but also by the ever-increasing focus on...
7
May
2018
Bionest
New Contender in Race to Develop Allogeneic CAR-T Treatments
Just months after negotiating the sale of autologous CAR-T pioneer Kite Pharma to Gilead for $11.9 billion, two of the executives who led Kite to success are back with a new company, a clinical-stage asset, and a portfolio of 16 preclinical therapeutic candidates, as well as substantial financing. This time, the focus is the development...
21
Nov
2017
Bionest
Giving Thanks in IO
The immuno-oncology (IO) field has a lot to be thankful for as the year comes to a close. Not only are PD-1/PDL-1 inhibitors being rapidly approved, their use is being extended into new indications and tumor types well beyond what people expected. From melanoma and lung cancer to bladder, gastric and liver cancer, drugs...
13
Nov
2017